A study to optimize the dose of sunitinib based on blood levels of the drug and its metabolite in kidney cancer
Not Applicable
- Conditions
- Health Condition 1: C649- Malignant neoplasm of unspecifiedkidney, except renal pelvis
- Registration Number
- CTRI/2020/03/023900
- Lead Sponsor
- Advanced Cancer for Treatment Research and Education
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1 Adults of age 18 years and above
2 Histologically or cytologically proven mRCC
3 Chemo-naïve patients eligible for single agent sunitinib
4 Patient willing to give written informed consent
Exclusion Criteria
1 Patient with malignancies other than mRCC
2 Patient received one or more dose of sunitinib previously
3 Patients with active HIV infection and serology positive for HBV,HCV ,HAV
4 History of severe liver disease or other uncontrollable medical condition
5.Patients on concomitant drugs which are CYP3A4 inducers or inhibitors
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method